Harnessing Characterization & Analytical Methods to Illuminate LNP Structure & Enable Stability, Integrity, & Efficacy for Regulatory Submissions & Next Generation Constructs
As RNA therapeutics move toward targeted delivery, multi-cargo constructs and gene editing, lipid nanoparticle characterization has become critical to understanding drug product quality, predicting performance and meeting regulatory expectations.
The 4th LNP Characterization & Analytical Development Summit was the only meeting dedicated entirely to solving the analytical challenges of LNP drug products.
If you're a scientist running the assays, instruments and methods every day, this was your opportunity to learn how peers at AbbVie, Merck, Genentech, Sanofi, Eli Lilly and Novo Nordisk tackle challenges ranging from SAXS and mass spectrometry to RiboGreen encapsulation efficiency. If you're leading an LNP pipeline, this was where your team could have stayed ahead of evolving analytical requirements, improve development readiness and gained practical insight into targeted LNPs, complex payloads and emerging modalities.
Over two days of practitioner-led case studies, panels and roundtables, you could have:
- Strengthened your control strategy by defining the critical quality attributes (CQAs) that actually predict potency, safety and efficacy
- Got practical answers on what's next for targeted LNPs, taRNA, in vivo CAR-T and gene editing LNPs
- Compared leading analytical platforms side by side at a neutral, independently run event
- Exchanged insights directly with experts from big pharma and next-generation biotech in a focused setting designed for meaningful discussion
You would have walked away with proven approaches, valuable industry connections and a clearer roadmap for advancing analytical development across your LNP pipeline.
A Snapshot of Previous Speakers
Attending Companies Included